Periodic Report Summary 2 - IMMUNOTHERAPY IN CML (Combined application of targeted therapy and immunotherapy in chronic myeloid leukaemia)
These data support the development of clinical protocols to induce cellular immune response against leukaemia antigens. Based on these data, we were successful in obtaining funding from Cancer Research UK to support a clinical study of PR1 and WT1 peptide vaccination in patients with CML on imatinib.